The erectile dysfunction is inability of the person to maintain erection during sexual intercourse. It can be due to the various physical and psychological reasons. The global erectile dysfunction drugs market can be segmented on the basis of therapeutics, product type, and distribution channel. On the basis of therapeutics, it is further segmented into existing and pipeline drugs. Existing drug segment is anticipated to witness robust growth on the account of various advantages associated with the drugs.

On the basis of mode of administration, it is further sub-segmented into injections, oral medications and topical medications. Oral medication is the leading segment in the global erectile dysfunction drugs. However, several medications are given orally to the patient and in turnlead to the high growth of the oral mode of administration. On the basis of distribution channel, it is segmented into online pharmacies, retail pharmacies and hospital pharmacies. Retail pharmacies are the major segment on the account of easy availability of drugs, low prices of drugs and expansion of pharmaceutical segment across the globe.

The global Erectile Dysfunction Drugs Market is anticipated to expand at a CAGR around 5.0% during 2017-2027. It is also anticipated to reach significant market size during forecast period. The rise in the patient across the globe on the account of lifestyle problems and psychological problems is anticipated to foster the market growth.

By region, North America accounted the largest market share of the erectile dysfunction drugs. The presence of key players along with the introduction of new drugs is anticipated to foster the market growth during forecast period. The high spending on R&D activities will also augment the market growth.

In Q4 2021, USA current-account deficit widened stood at $224.8 billion. However, in Q1 22, CAD rose by 29.6%, reached to $291.4 billion, adding $66.6 billion to the gap. Export of good and services increased by $25.7 billion to reach $1.03 trillion in the first quarter of 2022. However, goods and services deficit was $79.6 billion in June, down $5.3 billion from $84.9 billion in May, revised- reflecting some sight of relief. On the other hand, annual inflation rate in the country hit 8.5%. Energy CPI surged by 32.9% in July 2022, inflating the cost of logistic and some signs to disrupt supply chain whilst electricity cost upsurged by 15.2%, highest since Feb 2006. Apart from that, In July 2022, existing US home sales declined 5.9% to 4.81 million (seasonally adjusted annual rate), the lowest since May of 2020 and below market expectations of 4.89 million. As mortgage rate touches to peak 6%, sales for houses declined for a sixth consecutive month. Global energy crises to remain at focal point, pushing consumers to spend less on the products and services and save more.

On the other hand, the worst is expected to be seen in the European countries especially during 2022 winters. The energy and gas crises has already started grappling the region where in many Western European countries including Germany is looking for coal fired solutions to tackle the gas supply shortage, created by Russian-Ukraine conflict.

Amidst global concerns, market players have started looking for safe investments by holding on to the new technology and product launches. Factors like currency translation, disruption in global supply chain, Anti-China sentiments brewing across the globe, slowdown in Chinese economy, inflated products prices, USD getting stronger every week, decreasing purchasing power and strict measures taken by central banks/institutions across the world to ensure less spending and more saving, could hit the demand for the product and service badly in near future.

Healthcare Companies and Private Service Providers to have a minimal damage Caused by Inflation:

As US govt. remains committed to quality by spending more in the Medicaid and Medicare programs, incentives by govt. to medical devices, pharma companies and biotech to benefit the market players in short and long term goals. In 2021, U.S. spent $12,318/person on healthcare- highest amongst all OECD countries followed by Germany at $7,383. The federal government commitment towards healthcare systems to enable market players expanding their revenues and mitigating the risk posed by the inflation. 

Rising awareness and growing medication is anticipated to foster the market growth of erectile dysfunction drugs

The rising awareness about the disease and increasing disposable income enables the patient to seek better medical attention which indirectly is anticipated to foster market growth. The favorable guidelines issued regarding erectile dysfunction enables the patient to garner better information and diagnose the concerned disease. The availability of low cost drugsis expected to further enhance the market in the developing countries such as China and India. The key players operating in the market are launching new products with reduced side-effects.

The report titled “Erectile Dysfunction Drugs Market: Global Demand Analysis & Opportunity Outlook 2027” delivers the detailed overview of the global erectile dysfunction drugs market in terms of market segmentation therapeutics, by mode of administration, by distribution channel and by region.    

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

This report also provides the existing competitive scenario of some of the key players of the global erectile dysfunction drugs market which includes company profiling of key companies such as Pfizer, Inc., Dong-A ST Co., Ltd, Eli Lilly and Company, Bayer AG, VIVUS, INC., Teva Pharmaceutical Industries Ltd. SK chemicals, Meda Pharmaceuticals Inc., Apricus Biosciences, Inc., and Futura Medical plc..

The outlining enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global erectile dysfunction drugs market that is expected to help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.